Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, CAS 823202-99-9) and Argireline (Acetyl Hexapeptide-8) are both cosmetic expression-line peptides, but they target different mechanistic stories: Syn-Ake is often positioned around nicotinic acetylcholine receptor (nAChR) modulation inspired by waglerin research, while Argireline is widely marketed around SNAP-25 / neuromuscular signaling concepts. In finished products, many brands pair them at modest use levels rather than choosing one exclusively. Neither replaces injectable procedures; both belong in appearance-based topical claim lanes.
Why Formulators Compare Syn-Ake and Argireline
Purchasing and R&D teams frequently receive briefs asking for a “Botox-like peptide” without crossing into drug claims. Syn-Ake and Argireline dominate that conversation because both have long market history, supplier literature, and recognizable trade positioning. For identity and regulatory naming, start with the Syn-Ake hub article and the product page for CAS 823202-99-9.
| Dimension | Syn-Ake (CAS 823202-99-9) | Argireline (Acetyl Hexapeptide-8) |
|---|---|---|
| INCI / common name | Dipeptide Diaminobutyroyl Benzylamide Diacetate | Acetyl Hexapeptide-8 |
| Typical positioning | Expression-line / “snake peptide” story; nAChR-inspired mechanism in supplier literature | Expression-line / “Botox-like peptide” story; SNAP-25 pathway in supplier literature |
| Common physical form | Powder (diacetate salt) or diluted peptide solution from suppliers | Powder or solution; widely stocked globally |
| Typical literature use level (finished product) | Often discussed around ~0.5–4% of a supplier peptide solution, or equivalent active basis — validate against your COA | Often discussed around ~3–10% solution basis in leave-on serums — validate against your COA |
| pH window (general lab guidance) | Mildly acidic to near-neutral; avoid prolonged hot, high-pH hold | Similar mild pH preference; check supplier TDS |
| Pairing pattern | Frequently combined with Argireline in multi-peptide serums | Frequently combined with Syn-Ake, Matrixyl-class peptides, or HA |
| Claim caution | Avoid paralysis / injection equivalence language | Same — appearance-only cosmetic framing |
When Syn-Ake Is Often the Lead Peptide
- Briefs that already reference CAS 823202-99-9 or the full chemical name dipeptide diaminobutyroyl benzylamide diacetate.
- Products leaning into the temple-viper / waglerin-inspired narrative (with compliant synthetic-peptide wording).
- Eye-area or serum concepts where your team wants a distinct INCI from Argireline on the hero panel — see expression-line use cases.
- Formulas where you plan a multi-peptide stack and need mechanism diversity on the dossier.
When Argireline Is Often the Lead Peptide
- Cost-sensitive mass serums needing a well-known peptide INCI with broad supplier availability.
- Briefs that explicitly request Acetyl Hexapeptide-8 on the pack.
- Starter expression-line launches where marketing already owns Argireline language assets.
Pairing guidance and cool-down notes live in the Syn-Ake formulating guide. For finished-label language, cross-check claims writing guidance.
Formulation Practicalities Side by Side
| Lab question | Syn-Ake | Argireline |
|---|---|---|
| Add point | Cool-down phase below ~40 °C for many SOPs | Same conservative approach |
| Anionic surfactant cleansers | Peptide activity may be wasted in rinse-off; prefer leave-on | Same |
| Multi-peptide serum | Compatible in many water-based systems at modest levels | Compatible; watch total peptide load and preservative load |
| Stability testing | Monitor color, odor, pH drift, and peptide assay where available | Same |
| Documentation for OEM | Specify diacetate salt form, assay, and solution vs powder basis | Specify peptide content basis on COA |
FAQ
Can Syn-Ake and Argireline be used together in one serum?
Yes — many commercial formulas combine them at moderate levels. Treat totals as a budget for peptides, humectants, and preservation. See compatibility matrix guidance and use levels by format.
Which peptide is stronger?
Cosmetic products should not use “stronger than Botox” framing. Compare them on INCI story, supplier data you are authorized to cite, cost, and stability in your base — not on medical potency language.
Does Syn-Ake replace Argireline in reformulations?
Not automatically. Some brands swap for differentiation; others keep Argireline and add Syn-Ake. Run stability and panel tests before changing hero INCI order.
What should purchasing put on the PO?
For Syn-Ake: CAS 823202-99-9, INCI name, diacetate form, assay, and whether the quote is powder or pre-diluted solution. Request COA/TDS before scale-up.
Where do expression-line claims fit?
Keep copy in the appearance of expression lines lane. Claims writing for Syn-Ake lists safer patterns.
Related Resources
- What is Dipeptide Diaminobutyroyl Benzylamide Diacetate (Syn-Ake)?
- The Science Behind Syn-Ake (CAS 823202-99-9)
- Formulating Syn-Ake: Use Level, pH, Cool-Down & Argireline Pairing
- Writing Honest Syn-Ake Claims Language
- Syn-Ake Manufacturing & Quality Control
- Syn-Ake in Expression-Line Cosmetics
- Dipeptide Diaminobutyroyl Benzylamide Diacetate product page (CAS 823202-99-9)
- Cosmetic peptides category
- Contact Monuo Chemical for COA / quotation
- Syn-Ake compatibility with HA, niacinamide & retinol
- Syn-Ake use levels by product format
Disclaimer
This page is for cosmetic formulation education and B2B sourcing context. Use levels cited are typical literature or supplier-range starting points, not guaranteed recipes. Finished-product claims, labeling, and regulatory compliance remain the customer’s responsibility. Verify each lot against the supplied COA and SDS. Do not use medical, injectable, or drug claim language for topical peptide marketing.